EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas

Mingyuan Sun, Keshu Zhou, Junyuan Qi, Huilan Liu, Aizong Shen, Liangquan Geng, Fuling Zhou, Jianying Huang, Zi Chen, Ke Zhang, Lichuang Men, Danhua Cong und 4 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026-06 · 26 (6) · 388-398.e3

DOI: 10.1016/j.clml.2026.03.010 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-06. Verfasst von Mingyuan Sun und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Dis…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Proto-Oncogene Proteins c-bcl-2, Lymphoma, Non-Hodgkin, Antineoplastic Agents. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lisaftoclax is a novel BCL-2 inhibitor. This phase 1 trial (NCT03913949) evaluated the safety and preliminary efficacy of lisaftoclax in Chinese patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other non-Hodgkin lymphomas (NHL). PATIENTS AND METHODS: Lisaftoclax was administered orally in 28-day cycles, targeting daily doses of 20-800 mg for up to 24 cycles, using a daily ramp-up to minimize tumor lysis syndrome (TLS) risk. Patients with previous resistance to a BCL-2 inhibitor or exposure to a BCL-2 inhibitor in the most recent treatment line were excluded. Among 51 enrolled patients, 14 had CLL/SLL, 13 mantle cell lymphoma (MCL), and 4 marginal zone lymphoma (MZL). RESULTS: The maximum tolerated dose of lisaftoclax was not reached; neither dose-limiting toxicity nor TLS was observed. Common adverse events included anemia, neutropenia, and thrombocytopenia. Significant antitumor activity was observed in CLL/SLL (overall response rate [ORR] 71.4%, complete response [CR] 28.6%); MCL (ORR 50.0%, CR 20.0%); and MZL (ORR 50.0%, CR 0). Median progression-free survival was 7.9 (95% CI, 4.9-14.1) months for all patients and 18.6 (95% CI, 8.4-not reached [NR]) and 7.9 (95% CI, 2.0-NR) months for those with CLL/SLL and MCL, respectively. The median overall survival was NR (95% CI, 26.2-NR) for all patients. CONCLUSION: Lisaftoclax has a manageable safety profile and induces durable responses in R/R CLL/SLL and NHL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellProto-Oncogene Proteins c-bcl-2Lymphoma, Non-HodgkinAntineoplastic AgentsHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and overNeoplasm Recurrence, LocalEast Asian PeopleDioxanesNitrobenzenesPyrroles

Stichwörter der Autor:innen

BCL-2 inhibitorCLL/SLLRelapsed/refractorynon-Hodgkin lymphoma

Substanzen

Proto-Oncogene Proteins c-bcl-2Antineoplastic AgentsLisaftoclaxDioxanesNitrobenzenesPyrroles

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union M…
  • Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.
  • The First Affiliated Hospital of University of Science and Technology of China (USTC), Anhui Provincial Hospital, Hefei 230001, China.
  • Zhongnan Hospital, Wuhan University, Wuhan 430071, China.
  • Ascentage Pharma (Suzhou) Co., Ltd., Suzhou 215000, China.
  • Ascentage Pharma (Suzhou) Co., Ltd., Suzhou 215000, China; State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, Chi…

Zitieren

APA

Sun, M., Zhou, K., Qi, J., Liu, H., Shen, A., Geng, L., Zhou, F., Huang, J., Chen, Z., Zhang, K., Men, L., Cong, D., Lu, F., Yang, D., Zhai, Y., & Wang, J. (2026). Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas. Clinical Lymphoma Myeloma and Leukemia, 26(6), 388-398.e3. https://doi.org/10.1016/j.clml.2026.03.010

Vancouver

Sun M, Zhou K, Qi J, Liu H, Shen A, Geng L, et al. Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas. Clinical Lymphoma Myeloma and Leukemia. 2026;26(6):388-398.e3. doi:10.1016/j.clml.2026.03.010

BibTeX
@article{Sun2026,
  author = {Sun, Mingyuan and Zhou, Keshu and Qi, Junyuan and Liu, Huilan and Shen, Aizong and Geng, Liangquan and Zhou, Fuling and Huang, Jianying and Chen, Zi and Zhang, Ke and Men, Lichuang and Cong, Danhua and Lu, Fang and Yang, Dajun and Zhai, Yifan and Wang, Jianxiang},
  title = {Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {6},
  pages = {388--398.e3},
  doi = {10.1016/j.clml.2026.03.010}
}
Kostenlos starten →